Tuberculosis and Crohn's Disease Revisited

Area of Science:

• Gastroenterology
• Infectious Diseases
• Immunology

Background:

• Crohn's Disease (CD) and Intestinal Tuberculosis (ITB) present with overlapping clinical, endoscopic, radiological, and pathological features.
• Distinguishing between CD and ITB is diagnostically challenging, necessitating a combination of clinical suspicion and thorough investigations.
• Incorrect diagnosis has significant implications: immunosuppressive therapy can worsen ITB, while unnecessary anti-tuberculosis treatment can delay CD management.

Purpose of the Study:

• To review current literature on the differential diagnosis between CD and ITB.
• To summarize strategies for mitigating the risk of tuberculosis reactivation in patients with inflammatory bowel diseases (IBD) undergoing anti-Tumor Necrosis Factor Alpha (TNF-α) therapy.

Main Methods:

• Literature review of studies comparing CD and ITB diagnostic criteria.
• Analysis of existing guidelines and recommendations for TB screening in IBD patients.
• Synthesis of information on the impact of TNF-α inhibitors on TB risk.

Main Results:

• No single definitive test exists for differentiating ITB from CD.
• Clinical, endoscopic, radiological, and pathological findings often overlap, making diagnosis difficult.
• Anti-TNF-α therapy in IBD patients significantly increases the risk of TB reactivation, often extrapulmonary or disseminated.

Conclusions:

• Accurate differentiation between CD and ITB is critical for appropriate patient management.
• Screening for latent TB is strongly recommended for IBD patients initiating anti-TNF-α therapy.
• Implementing effective screening strategies is essential to reduce TB reactivation risk in this vulnerable population.